In practice, choice among PDGFR-sparing options should be individualized: asciminib may be preferred for patients with the T315I mutation or in whom its safety profile and interaction plan are acceptable (e.g., when cytopenia risk and pancreatitis risk are manageable and drug–drug interactions can be mitigated), and BOS may be preferable when rapid disease control is needed and gastrointestinal (GI) toxicities can be managed. This evidence concerns the gene PDGFRB and pancreatitis.